Stock Decline: Boston Scientific shares have tumbled more than 50 percent from recent peaks, now hovering near $48 following a guidance reduction. Investors on social media are scrutinizing the impact of slower growth in key segments like WATCHMAN and ablation technologies.
Market Analysis: Analysts maintain elevated price targets between $84 and $135, fueling debate over whether the selloff has gone too far. Discussions emphasize the company's strong position in electrophysiology and diversified med-tech portfolio as buffers against short-term pressures.
Investor Outlook: Participants describe the pullback as creating an appealing entry point for long-term positions, with some highlighting temporary acquisition concerns and market share shifts. Overall, the tone reflects measured confidence in eventual recovery.
Note: This discussion summary was generated from an AI condensation of post data.
Boston Scientific Insider Trading Activity
Boston Scientific insiders have traded $BSX stock on the open market 6 times in the past 6 months. Of those trades, 4 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 2 sales selling 160,901 shares for an estimated $15,043,394.
- DAVID C HABIGER has made 2 purchases buying 4,450 shares for an estimated $251,098 and 0 sales.
- EDWARD J LUDWIG purchased 3,580 shares for an estimated $202,914
- CHERYL PEGUS purchased 1,770 shares for an estimated $99,987
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Boston Scientific Revenue
Boston Scientific had revenues of $5.2B in Q1 2026. This is an increase of 11.58% from the same period in the prior year.
You can track BSX financials on Quiver Quantitative's BSX stock page.
You can access data on BSX stock through the Quiver Quantitative API.
Boston Scientific Congressional Stock Trading
Members of Congress have traded $BSX stock 8 times in the past 6 months. Of those trades, 6 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 6 times. They made 5 purchases worth up to $75,000 on 05/29, 05/19, 05/11, 02/10, 01/30 and 1 sale worth up to $15,000 on 12/24.
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 12/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Boston Scientific Hedge Fund Activity
We have seen 848 institutional investors add shares of Boston Scientific stock to their portfolio, and 998 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 23,160,546 shares (-23.8%) from their portfolio in Q1 2026, for an estimated $1,433,869,402
- CAPITAL WORLD INVESTORS removed 11,841,837 shares (-43.6%) from their portfolio in Q1 2026, for an estimated $733,128,128
- WELLINGTON MANAGEMENT GROUP LLP added 9,124,317 shares (+94.0%) to their portfolio in Q1 2026, for an estimated $564,886,465
- FRANKLIN RESOURCES INC added 8,822,659 shares (+155.4%) to their portfolio in Q1 2026, for an estimated $546,210,818
- FISHER ASSET MANAGEMENT, LLC removed 8,687,613 shares (-95.1%) from their portfolio in Q1 2026, for an estimated $537,850,120
- TWO SIGMA INVESTMENTS, LP added 6,939,887 shares (+280.8%) to their portfolio in Q1 2026, for an estimated $429,648,404
- MILLENNIUM MANAGEMENT LLC removed 6,926,986 shares (-61.5%) from their portfolio in Q1 2026, for an estimated $428,849,703
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Boston Scientific Government Contracts
We have seen $23,431,950 of award payments to $BSX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION: $1,260,000
- Y90 GLASS MICROSPHERES: $1,227,000
- Y90 THERASPHERE: $1,155,000
- VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS: $954,240
- THERASPHERE YTTIRUM-90 (Y-90) GLASS: $833,910
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Boston Scientific Analyst Ratings
Wall Street analysts have issued reports on $BSX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 06/03/2026
- Needham issued a "Buy" rating on 02/05/2026
- Truist Securities issued a "Buy" rating on 02/05/2026
- RBC Capital issued a "Outperform" rating on 12/17/2025
To track analyst ratings and price targets for Boston Scientific, check out Quiver Quantitative's $BSX forecast page.
Boston Scientific Price Targets
Multiple analysts have issued price targets for $BSX recently. We have seen 22 analysts offer price targets for $BSX in the last 6 months, with a median target of $84.5.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $64.0 on 06/04/2026
- Marie Thibault from BTIG set a target price of $65.0 on 06/03/2026
- William Plovanic from Canaccord Genuity set a target price of $70.0 on 06/01/2026
- Larry Biegelsen from Wells Fargo set a target price of $55.0 on 05/28/2026
- Matt Miksic from Barclays set a target price of $89.0 on 05/28/2026
- Mike Kratky from Leerink Partners set a target price of $74.0 on 05/28/2026
- Joanne Wuensch from Citigroup set a target price of $70.0 on 05/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
